American National Bank & Trust Co. VA Purchases Shares of 10,274 Pfizer Inc. (NYSE:PFE)

American National Bank & Trust Co. VA purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,274 shares of the biopharmaceutical company’s stock, valued at approximately $285,000.

Several other institutional investors have also recently added to or reduced their stakes in PFE. GoalVest Advisory LLC raised its position in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC increased its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC increased its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the 4th quarter valued at $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, June 26th. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $35.54.

Pfizer Stock Down 0.5 %

Shares of NYSE PFE opened at $27.70 on Friday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The business has a 50-day simple moving average of $28.04 and a two-hundred day simple moving average of $27.71. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The company has a market cap of $156.96 billion, a P/E ratio of -461.59, a P/E/G ratio of 1.09 and a beta of 0.69.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the company earned $1.23 EPS. The firm’s revenue was down 19.5% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.06%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.